• Journal of the Korean Wood Science and Technology
• /
• 제1권2호
• /
• pp.3-10
• /
• 1973

This study was carried out to examine the characeristics of waste sanders(S)from. plywood and pre-finishing plywood surface sanding and double saw finishing, as a new extander in urea-formaldehyde resin(UFR) in plywood adhesive, and to focus, adhesive strength using the glue extended with milled sanders(MS) as extender, leveling the optimum amount of MS to be added, and examining the physical properties of glue extended MS & S. Also economical good feasibility of substitution for wheat flour(WF) with MS as a new extender is analyzed and presented in details. Selecting three standard samples of 80, 100 and 180 mesh, sorking them in distilled water at $20^{\circ}C$, 24 hours, redrying at $105^{\circ}C$ and rescreening the sample with standard screen, again, the 3 samples of 80, 100, and 180 mesh are passed 23 percent through 80 mesh sander standard sample 27 percent through on 100 mesh and only 10.9 percent through 180 mesh, respectively. The particle size of retained parts are greater in size of redried form. It seems undoubtly that particles to be extended in glue are got swollen and become greater in size and coarser in shape. The shape of fresh S particles are irregular thin needle with small scale, as shown in Figure 5. PFS are so finer than plywood S that only 9.8 percent of the S retained on 100 mest screen, 24. 30 percent on 100-160 mesh, and 65.9% on 160-180 mesh. But particle size of the fresh S is large enough to make the viscosity of glue direct extended with S too high to apply it glue spreader. The glue extended with milled sanders(MS). 3 hours milled PFS or 6 hours milled plywood S, having particle sizes shown in Tables 7 and 8, as ratio of Reain/MS/WF/water: 100/8/8/10, indicate good viscosity of 16 to 24 ps, as shown in Figure 5, for applying direct to glue spreader, have high tensile-shear strength (adhesive strength), 102.4 kp/$cm^2$, and 94 percent wood failure.

• Tuberculosis and Respiratory Diseases
• /
• 제81권2호
• /
• pp.148-155
• /
• 2018

Background: Although targeted therapy and immuno-oncology have shifted the treatment paradigm for lung cancer, platinum-based combination is still the standard of care for advanced non-small cell lung cancer (NSCLC). Pemetrexed continuation maintenance therapy has been approved and increasingly used for patients with nonsquamous NSCLC. However, the efficacy of this strategy has not been proven in patients without driving mutations. The objective of this study was to compare the clinical benefit of pemetrexed continuation maintenance to conventional platinum-based doublet in epidermal growth factor receptor (EGFR)-negative lung adenocarcinoma. Methods: A total of 114 patients with EGFR-negative lung adenocarcinoma who were treated with platinum doublet were retrospectively enrolled. We compared the survival rates between patients received pemetrexed maintenance after four-cycled pemetrexed/cisplatin and those received at least four-cycled platinum doublet without maintenance chemotherapy as a first-line treatment. Results: Forty-one patients received pemetrexed maintenance and 73 received conventional platinum doublet. Median progression-free survival (PFS), which was defined as the time from the day of response evaluation after four cycles of chemotherapy to disease progression or death, was significantly higher in the pemetrexed maintenance group compared to conventional group (5.8 months vs. 2.2 months, p<0.001). Median overall survival showed an increasing trend in the pemetrexed maintenance group (22.3 months vs. 16.1 months, p=0.098). Multivariate analyses showed that pemetrexed maintenance chemotherapy was associated with better PFS (hazard ratio, 0.73; 95% confidence interval, 0.15-0.87). Conclusion: Compared to conventional platinum-based chemotherapy, premetrexed continuation maintenance treatment is associated with better clinical outcome for the patients with EGFR wild-type lung adenocarcinoma.

• Radiation Oncology Journal
• /
• 제36권4호
• /
• pp.304-316
• /
• 2018

Purpose: The indication of elective neck treatment (ENT) for clinically N0 (cN0) paranasal sinus (PNS) carcinoma remains unclear. We aimed to investigate different treatment outcomes regarding ENT and propose optimal recommendations for ENT. Materials and Methods: We identified patients with cN0 PNS carcinoma who underwent curative-intent treatment between 1992 and 2015. Survival outcomes and pattern of failure were compared between patients who received ENT and those who did not. We sought to identify significant patient or pathologic factors regarding treatment outcomes. Results: Among 124 patients meeting the inclusion criteria, 40 (32%) received ENT ('ENT (+) group') and 84 (68%) did not ('ENT (-) group'). With a median follow-up of 54 months, the 5-year overall survival (OS) was 67%, and the 5-year progression-free survival (PFS) was 45%. There was no significant difference between the ENT (+) and ENT (-) groups regarding OS (p = 0.67) and PFS (p = 0.50). Neither group showed a significantly different pattern of failure, including regional failure (p = 0.91). There was no specific benefit, even in the subgroups analysis by tumor site, histologic type, and T stage. Nevertheless, patients who ever had regional and/or distant failure showed significantly worse prognosis. Conclusion: ENT did not significantly affect the survival outcome or pattern of failure in patients with cN0 PNS carcinomas, showing that ENT should not be generalized in this group. However, further discussion on the optimal strategy for ENT should continue because of the non-negligible regional failure rates and significantly worse prognosis after regional failure events.

• 기술혁신학회지
• /
• 제15권1호
• /
• pp.105-128
• /
• 2012

본 논문에서는 특허맵 분석 데이터 구축 과정에서 필요한 효율적인 노이즈 제거방법과 신뢰도가 향상된 기술수준 평가를 제안한다. 과거 수작업으로만 진행하였던 노이즈 제거 과정을 논리 연산자 AND를 활용하여 엑셀 VBA(Visual Basic Application)에서 프로그램화 하여 효율적으로 제거하여 유효 데이터를 획득할 수 있게 된다. 신뢰도가 향상된 특허의 기술수준 평가를 위하여 평균 청구항 수, 특허 패밀리 사이즈(PFS: Patent Family Size), 특허당 인용도 지수(CPP: Cites per Patent), 삼극특허, 규격화 특허경쟁력 지수(stdPCPI: Standardization Patent Diversification Index), haF-index(Hirsch a Family index)등을 사용하게 된다. 제안된 효율적인 노이즈 제거 작업을 적용한 결과는 획득된 특허 데이터의 노이즈 비율이 10% 미만으로 나타나서 데이터의 신뢰도가 높음이 확인되었다. 제안된 기술수준 평가 지수를 적용한 결과는 공통적으로 확인할 수 있는 정보에 의해 기술수준 평가를 산출함으로써 신뢰도가 향상된 균형적 기술수준 평가가 가능함을 확인할 수 있었다.

• Journal of Korean Neurosurgical Society
• /
• 제56권3호
• /
• pp.194-199
• /
• 2014

Objective : Meningioma is the second most common primary central nervous system neoplasm. In contrast, chordoid meningioma is rare; due to the paucity of cases, little is known about its clinical features or treatment outcomes. The objectives of this study were to describe the clinical characteristics and outcomes for patients with chordoid meningioma. Methods : In total, 16 patients, with newly diagnosed chordoid meningioma who underwent surgical excision between 1999 and 2012 were included. We retrospectively evaluated the medical records, radiological findings, and pathological findings. The median follow-up period was 56.5 (range, 3-170) months. The MIB-1 labeling index ranged from 1 to 26.60% (median, 5.04). Results : Simpson grade I, II, and III resections were performed in four, nine, and three patients, respectively. The overall recurrence rate was 37.5%. Overall progression-free survival (PFS) after resection was 94.7 months (95% CI=62.9-126.6). Of the 4 patients with Simpson grade I resection, recurrence occurred in one patient. Among the Simpson grade II and III resection groups, eight patients underwent adjuvant radiation therapy and they showed significantly longer PFS (121 months, 95% CI=82.1-159.9) than the patients who underwent surgery alone (40.5 months, 95% CI=9.6-71.3) by the log-rank test (p<0.05). Conclusion : Chordoid meningiomas are difficult to manage and have a high rate of recurrence. Complete resection of the tumor is a key determinant of better outcomes. Adjuvant radiation therapy is recommended, eparticulary when Simpson grade I resection was not achieved.

• Tuberculosis and Respiratory Diseases
• /
• 제82권3호
• /
• pp.211-216
• /
• 2019

Background: Docetaxel is one of the standard treatments for advanced non-small cell lung cancer. Docetaxel is usually administered in a 3-week schedule, but there is significant toxicity. In this phase II clinical study, we investigated the efficacy and safety of a 4-weekly schedule of docetaxel monotherapy, as first-line chemotherapy for advanced squamous cell carcinoma in elderly lung cancer patients. Methods: Patients with stage IIIB/ IV lung squamous-cell carcinoma age 70 or older, that had not undergone cytotoxic chemotherapy were enrolled. Patients received docetaxel $25mg/m^2$ on days 1, 8, and 15, every 4 weeks. Primary endpoint was the objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity profiles. Results: A total of 19 patients were enrolled. Among 19 patients, 17 were for evaluated efficacy and safety. In the intent-to-treat population, ORR and disease control rate (DCR) were 11.8% and 47.1%, respectively. In the response evaluable population, ORR was 16.7% and DCR was 66.7%. Median PFS and OS were 3.1 months and 3.3 months, respectively. There were three adverse grade 3/4 events. Grade 1 neutropenia was reported in one patient. Conclusion: Our data failed to demonstrate efficacy of a 4-weekly docetaxel regimen, in elderly patients with a poor performance status. However, incidence of side effects, including neutropenia, was lower than with a 3-week docetaxel regimen, as previously reported.

• Tuberculosis and Respiratory Diseases
• /
• 제82권1호
• /
• pp.62-70
• /
• 2019

Background: Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancers have emerged as key predictive biomarkers in EGFR tyrosine kinase inhibitor (TKI) treatment. However, a few patients with wild-type EGFR also respond to EGFR TKIs. This study investigated the factors predicting successful EGFR TKI treatment in lung adenocarcinoma patients with wild-type EGFR. Methods: We examined 66 patients diagnosed with lung adenocarcinoma carrying wide-type EGFR who were treated with EGFR TKIs. The EGFR gene copy number was assessed by silver in situ hybridization (SISH). We evaluated the clinical factors and EGFR gene copy numbers that are associated with a favorable clinical response to EGFR TKIs. Results: The objective response rate was 12.1%, while the disease control rate was 40.9%. EGFR SISH analysis was feasible in 23 cases. Twelve patients tested EGFR SISH-positive, and 11 were EGFR SISH-negative, with no significant difference in tumor response and survival between EGFR SISH-positive and -negative patients. The overall median progression-free survival (PFS) and overall survival (OS) of 66 patients were 2.1 months and 9.7 months, respectively. Female sex and Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1 were independent predictors of PFS. ECOG PS 0-1 and a low tumor burden of extrathoracic metastasis were independent predictors of good OS. Conclusion: Factors such as good PS, female sex, and low tumor burden may predict favorable outcomes following EGFR TKI therapy in patients with EGFR wild-type lung adenocarcinoma. However, EGFR gene copy number was not predictive of survival.

• 정보보호학회논문지
• /
• 제17권2호
• /
• pp.103-114
• /
• 2007

기존의 이동 네트워크에서는 링크 계층에서 액세스 인증과 네트워크 계층에서 FMIPv6의 핸드오버 인증이 독립적으로 수행되어 AAA 인증 서버의 오버헤드 증가 및 잦은 핸드오버 인증 수행으로 인증 지연을 초래하는 문제점이 있었다. 본 논문에서는 이기종 FMIPv6 기반의 이동 네트워크에서 이동 노드 주도형 통합 핸드오버 인증 프로토콜을 제안한다. 제안기법은 FMIPv6 환경에서 이동 노드가 직접 핸드오버 인증키를 생성하여 인증 서버를 통해 안전하게 NAR로 전송하고, NAR에서는 AP들과 계층적 키 관리 구조를 갖는다. 이동 노드에서 생성한 인증키는 FMIPv6에서 핸드오버 할 때 PAR과 이동 노드 사이에서 FBU 메시지를 안전하게 전송할 수 있고, NAR에서 계층적 키 관리를 통해 이동 노드의 링크 액세스 인증을 수행할 수 있다. 제안 기법은 이동 노드에서 핸드오버 인증키 생성, AAA 서버 기능의 단순화로 AAA 서버의 오버헤드를 줄이고, 잦은 핸드오버 인증 수행 절차를 감소시킴으로써 핸드오버 인증 지연 시간을 감소시킨다. 또한 제안 기법은 PFS, PBS를 제공하고 DoS 공격에 안전하다.

• The Journal of Korean Physical Therapy
• /
• 제33권6호
• /
• pp.292-296
• /
• 2021

Purpose: The purpose of this study was to investigate the exercise effect of two types of training with a recumbent cycle ergometer on ankle muscle strength (dorsiflexor strength, DFS; dorsiflexor strength/weight, DFS/kg; plantar flexor strength, PFS; and plantar flexor strength/weight, PFS/kg) in healthy male subjects. Methods: Twenty-three healthy males (27.91±8.66 yr) were randomly allocated into two groups (high-intensity interval training (HIIT), and aerobic exercise training (AET) after the first measurement. The subjects were trained for 24 sessions (40 min/rep, three times/week) and ankle strength was measured for a second time. Two-way mixed model analysis of variance (ANOVA) was used to identify significant differences between changes in ankle muscle strength between before and after training (within factors) in the HIIT and AET groups (between factors). The statistical significance level was set at α=0.05. Results: In both HIIT and AET groups, all variables of ankle muscle strength were significantly increased after training compared to before training (p=0.001). However, there were no differences in all variables of ankle strength between the HIIT and AET group (p>0.05). Conclusion: Both types (HIIT and AET) of recumbent cycle exercise training could be effective training methods to increase ankle muscle strength in healthy individuals, and the HIIT type with high intensity and low frequency pedaling could be recommended more to strengthen ankle muscles.

• Journal of Gastric Cancer
• /
• 제22권4호
• /
• pp.408-417
• /
• 2022

Purpose: Treatment options are limited after the failure of first-and second-line treatments in patients with HER2⁺ metastatic gastric cancer (mGC). The present study aimed to explore the efficacy, safety, and prognostic factors of apatinib efficacy as a third-line therapy for patients with human epithelial growth factor receptor 2-positive (HER2⁺) mGC. Materials and Methods: A total of 59 HER2⁺ mGC patients who received apatinib as third-line therapy were retrospectively enrolled in this two-center, single-arm, cohort study; the clinical response, survival data, and adverse events were retrieved. Results: The median progression-free survival (PFS) was 5.2 months (95% confidence interval [CI], 3.9-6.5), and the median overall survival (OS) was 8.2 months (95% CI, 6.6-9.8) Furthermore, forward stepwise multivariate Cox regression analysis showed that a higher Eastern Cooperative Oncology Group performance status score and multiple metastases were independently correlated with decreased PFS and OS (both P<0.05). The main adverse events were leukopenia (45.8%), hypertension (44.1%), thrombocytopenia (39.0%), hand-foot syndrome (37.3%), and elevated transaminase (33.9%). Grade 3 adverse events mainly included hypertension (5.1%) and neutropenia (5.1%); grade 4 adverse events did not occur. Conclusions: Apatinib is efficient and well tolerated in patients with HER2⁺ mGC as a third-line treatment, suggesting that it may be a candidate of choice for these patients.